Danner Laboratory

Executive Summary

Danner Laboratory is a San Francisco-based private company developing CTCReveal, a liquid biopsy platform for the detection and analysis of circulating tumor cells (CTCs). CTCReveal aims to provide a minimally invasive alternative to traditional tissue biopsies by enabling cancer therapy selection, prognosis, and treatment monitoring through a simple blood test. Founded in 2020, the company operates at the intersection of neuroscience and genetics & genomics, though its primary focus is oncology. While still in early stages without disclosed funding or pipeline milestones, the platform has the potential to address significant unmet needs in cancer diagnostics by offering real-time, repeatable insights into tumor dynamics. The company's progress will depend on clinical validation, regulatory clearance, and commercial partnerships.

Upcoming Catalysts (preview)

• Q3 2026Initial Clinical Validation Data for CTCReveal40% success
• H2 2026Strategic Partnership or Licensing Deal with Diagnostic or Pharma Company50% success
• Q4 2026Series A Funding Announcement60% success